Navigation Links
Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
Date:7/29/2008

y and with partners, including Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, the timing and receipt of payments and fees, if any, from Arena's collaborators, and Arena's ability to redeem with common stock any outstanding shares of its series B convertible preferred stock. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward- looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable la
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
2. ThreeWire Expands Presence in the Pharmaceutical Arena
3. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
4. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
7. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
8. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
9. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
10. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
11. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... The North America Thermal Protective ... for detailed analysis of the growth trends and ... $616.3 million by 2018, growing at a CAGR ... through the TOC of the North America Thermal ... of the in-depth analysis and industry segmentation supported ...
(Date:11/26/2014)... NEW YORK , Nov. 26, 2014 ... Healthcare may indicate the company is looking to expand ... any further sales.  The healthcare market research firm says ... according to Kalorama Information,s biennial survey of the IVD ... year, and any change in its composition would likely ...
(Date:11/26/2014)... The Alliance for Safe Biologic ... European physicians at the "1 ST EuropaBio ... at the Spanish Ministry of Health, Social Services ... the Spanish Bioindustry Association (ASEBIO), included regulators from ... oncology and rheumatology societies, representatives from a hospital ...
(Date:11/26/2014)... The ETC (Emerging Technology Centers) http://www.etcbaltimore.com ... today that applications for AccelerateBaltimore™ (AB) 2015 program ... have a big idea?,” asked ETC’s President Deb ... it. AccelerateBaltimore helps you and your big idea ... weeks.” Interested game changers with “big ideas” ...
Breaking Biology Technology:The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 2The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 3Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2ASBM Presents European Physicians Survey at Spanish Ministry of Health 2AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3
... California, and AMSTERDAM, January 8 ,Agendia, a world ... of Kurt Schmidt, CPA, MBA, as the company,s ... "Kurt is an exceptional addition to our team ... and Chief Executive Officer. "With his,extensive financial management ...
... Inc. announced today the dosing of the first ... AEG35156, their targeted antisense therapeutic in mid-stage development ... "A Phase 2, Multicenter, Open-Label, Randomized Study of ... Given In Combination With Carboplatin/Paclitaxel or the Combination ...
... (Nasdaq: DNDN ) today announced that management will ... San Francisco on Thursday, January 15, 2009 at 11:00 a.m. ... will be accessible through the Investor Relations section of the ... listen to the live webcast, it will be archived on ...
Cached Biology Technology:Agendia Appoints New Chief Financial Officer 2Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer 2
(Date:11/4/2014)... – A majority of Madagascar,s 101 species of lemurs ... consequences for the rainforests they call home. A new ... lemurs can have on rainforest tree populations, which raises ... on the region,s rich biodiversity. , A large proportion ... lemurs. Lemurs in turn disperse the seeds of ...
(Date:11/3/2014)... University of Colorado Cancer Center study published ... of Sciences describes the activity of a recently ... 37 or IL-37. It has been known to limit ... the adaptive immune system: IL-37 inhibits the ability of ... , "Knowing this mechanism that underlies IL-37,s effect on ...
(Date:11/2/2014)... World , James Dacey explores the ways in which ... their innovations from the lab into the commercial market. ... start-up companies as they move from prototype to product ... factors: physics-based inventions are usually far from market-ready when ... a lot more complicated than had been originally thought. ...
Breaking Biology News(10 mins):Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3PNAS: From HIV to cancer, IL-37 regulates immune system 2The 'valley of death' facing physics start-ups 2
... Americans with high blood pressure, more help is on the ... October 2010 print issue of The FASEB Journal ... arachidonic acid in our blood vessel walls to create a ... turns off genes responsible for vascular inflammation and ultimately relaxes ...
... USDA,s National Institute of Food and Agriculture awarded nearly ... assistance programs. "The United States is a major ... the world who are suffering during emergency situations," said ... and Agriculture (NIFA). "These projects will improve the nutritional ...
... largest renewable water resource for humans and a crucible of ... to a new global analysis. The report, published today ... first to simultaneously account for the effects of such things ... and the introduction of exotic species on the health of ...
Cached Biology News:Scientists discover a new way our bodies control blood pressure: the P450-EET system 2Report casts world's rivers in 'crisis state' 2Report casts world's rivers in 'crisis state' 3Report casts world's rivers in 'crisis state' 4
PKC Sampler Kit 10 mu g each...
Golgi Sampler Kit 10g each...
Umbilical cord blood eosinophils, For immunohistochemistry (IHC)...
Monocyte-derived dendritic cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Dendritic Cells...
Biology Products: